ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial

Zheng, Yabing; Cao, Wen-Ming; Shao, Xiying; Shi, Yanxia; Cai, Li; Chen, Wenyan; Liu, Jian; Shen, Peng; Chen, Yiding; Wang, Xian; Li, Huiping; Li, Man; Chen, Zhanhong*; Wang, Xiaojia*哈尔滨医科大学; 浙江大学; 中山大学; 1
Nature Communications2023-12-14DOI: 10.1038/s41467-023-44140-y
7阅读
引用收藏
分享

摘要

The role of pyrotinib in the treatment of HER2-positive metastatic breast cancer (MBC) has been well-established. This multicenter, single-arm phase II trial (NCT03876587) aimed to assess the benefit of pyrotinib plus docetaxel as a first-line treatment for HER2-positive MBC. Women with HER2-positive MBC who had not undergone HER2 blockade or chemotherapy for metastatic disease were enrolled in the study and received daily oral pyrotinib 400 mg plus intravenous docetaxel 75 mg/m2 every 3 weeks. The primary endpoint was the objective response rate (ORR), secondary endpoints included progression-free survival (PFS), duration of response (DoR), clinical benefit rate (CBR), overall survival (OS) and safety. From June 2019 to June 2021, 79 patients were enrolled. The confirmed ORR was 79.7% (95% confidence interval [CI], 70.8-88.6), and the CBR was 87.3% (95%CI, 80.0-94.6) in the intention-to-treat population. The pre-specified primary endpoint was met. The median DoR was 15.9 months (interquartile range, 8.3-19.5); the median PFS was 16.0 months (95% CI, 11.2-20.8), and the median OS was not reached. The most common grade >= 3 treatment-related adverse events observed were leukopenia (29.1%), neutropenia (27.8%), and diarrhea (21.5%). This study demonstrates that pyrotinib plus docetaxel show an acceptable safety profile and promising antitumor activity as a first-line treatment option for patients with HER2-positive MBC. @@@ HER2 targeted therapy combined with chemotherapy represents a standard approach for treating HER2-positive metastatic breast cancer (MBC). Here the authors report the results of a phase II trial of the small molecule tyrosine kinase inhibitor pyrotinib plus docetaxel as a first-line treatment for HER2-positive MBC.

学科与关键词

关键词
NERVOUS-SYSTEM METASTASESTYROSINE KINASE INHIBITORDOUBLE-BLINDOPEN-LABELTRASTUZUMABPERTUZUMABLAPATINIBCHEMOTHERAPYMULTICENTERCLEOPATRA
相关
加载中…
  • Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
    Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Liu, Hu; Cheng, Ying; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Ye, Changsheng; Dong, Fangli; Wu, Shuchao; Zhu, Xiaoyu; Xu, Binghe*BRITISH MEDICAL JOURNAL, 2023, 383: e076065.被引 3
  • Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
    Xie, Yizhao; Li, Yi; Ting, Luo; Sang, Die; Yuan, Peng; Li, Wei; Li, Huihui; Ge, Rui*; Wang, Biyun*Frontiers in Oncology, 2021, 11: 699333.被引 4
  • Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
    Li, Yiqun; Tong, Zhongsheng; Wu, Xinhong; Ouyang, Quchang; Cai, Li; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Niu, Zhaofeng; Wang, Qitang; Xu, Binghe*International Journal of Cancer, 2023, 153(10): 1809-1818.
查看全部 →

发表信息

论文状态
公开发表
期刊
Nature Communications
发表日期
2023-12-14
卷期
第 14 卷, 第 1 期
页码
8314
DOI
10.1038/s41467-023-44140-y
语言
ENGLISH
成果收录
SCIE
资助标注
This study was supported by Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.

作者

  • Z

    Zheng, Yabing (第一作者)

    zhejiang canc hosp

  • C

    Cao, Wen-Ming

    zhejiang canc hosp

查看全部 14 位作者收起作者
  • S

    Shao, Xiying

    zhejiang canc hosp

  • S

    Shi, Yanxia

    sun yat sen univ

  • C

    Cai, Li

    harbin med univ

  • C

    Chen, Wenyan

  • L

    Liu, Jian

    fujian canc hosp

  • S

    Shen, Peng

    1 · zhejiang univ

  • C

    Chen, Yiding

    2 · zhejiang univ

  • W

    Wang, Xian

  • L

    Li, Huiping

  • L

    Li, Man

    2 · dalian med univ

  • C

    Chen, Zhanhong (通讯)

    zhejiang canc hosp

  • W

    Wang, Xiaojia (通讯)

    zhejiang canc hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417